Loading…
A New Device Improves Signs and Symptoms of TMD
Background. Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. Methods. 50 females with myofascial TMD accordi...
Saved in:
Published in: | Pain research & management 2019-05, Vol.2019 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | |
container_start_page | |
container_title | Pain research & management |
container_volume | 2019 |
creator | Cattaneo, Ruggero Pietropaoli, Davide Cooper, Barry C Cappare, Dino Ortu, Eleonora Monaco, Annalisa |
description | Background. Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. Methods. 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. Results. T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p = 0.003) and maximum velocity in mouth opening (p = 0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. Conclusions. After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites. |
doi_str_mv | 10.1155/2019/5646143 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_22149c4979134f78a7dccfa557e10462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A612580121</galeid><doaj_id>oai_doaj_org_article_22149c4979134f78a7dccfa557e10462</doaj_id><sourcerecordid>A612580121</sourcerecordid><originalsourceid>FETCH-LOGICAL-d319t-b89176b1af04c0d816391665eff8e195b97fb08fbc221a6a2c4f0c26131f77713</originalsourceid><addsrcrecordid>eNptjU1Lw0AQhhdRsFZv_oCA4C3tzn5mj6X1o1D10HoOm81uuyXJlmys9N8brYcKMocZXp73GYRuAY8AOB8TDGrMBRPA6BkagIIsBU7oeX8TTFMhBb9EVzFuMWaQYTpA40nyaj-Tmd17Y5N5vWvD3sZk6ddNTHRTJstDvetCHZPgktXL7BpdOF1Fe_O7h-j98WE1fU4Xb0_z6WSRlhRUlxaZAikK0A4zg8sMBFUgBLfOZRYUL5R0Bc5cYQgBLTQxzGFDBFBwUkqgQzQ_esugt_mu9bVuD3nQPv8JQrvOddt5U9m8NzBlmJIKKHMy07I0xmnOpQXMBOldd0fXWve4b1zoWm1qH00-EUB4hoF8fxz9Q_VT2tqb0Fjn-_xP4f6ksLG66jYxVB-dD008Bb8Ap3F2iQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A New Device Improves Signs and Symptoms of TMD</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><source>Wiley-Blackwell Open Access Titles(OpenAccess)</source><creator>Cattaneo, Ruggero ; Pietropaoli, Davide ; Cooper, Barry C ; Cappare, Dino ; Ortu, Eleonora ; Monaco, Annalisa</creator><creatorcontrib>Cattaneo, Ruggero ; Pietropaoli, Davide ; Cooper, Barry C ; Cappare, Dino ; Ortu, Eleonora ; Monaco, Annalisa</creatorcontrib><description>Background. Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. Methods. 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. Results. T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p = 0.003) and maximum velocity in mouth opening (p = 0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. Conclusions. After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites.</description><identifier>ISSN: 1203-6765</identifier><identifier>EISSN: 1918-1523</identifier><identifier>DOI: 10.1155/2019/5646143</identifier><language>eng</language><publisher>John Wiley & Sons, Inc</publisher><ispartof>Pain research & management, 2019-05, Vol.2019</ispartof><rights>COPYRIGHT 2019 John Wiley & Sons, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cattaneo, Ruggero</creatorcontrib><creatorcontrib>Pietropaoli, Davide</creatorcontrib><creatorcontrib>Cooper, Barry C</creatorcontrib><creatorcontrib>Cappare, Dino</creatorcontrib><creatorcontrib>Ortu, Eleonora</creatorcontrib><creatorcontrib>Monaco, Annalisa</creatorcontrib><title>A New Device Improves Signs and Symptoms of TMD</title><title>Pain research & management</title><description>Background. Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. Methods. 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. Results. T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p = 0.003) and maximum velocity in mouth opening (p = 0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. Conclusions. After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites.</description><issn>1203-6765</issn><issn>1918-1523</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptjU1Lw0AQhhdRsFZv_oCA4C3tzn5mj6X1o1D10HoOm81uuyXJlmys9N8brYcKMocZXp73GYRuAY8AOB8TDGrMBRPA6BkagIIsBU7oeX8TTFMhBb9EVzFuMWaQYTpA40nyaj-Tmd17Y5N5vWvD3sZk6ddNTHRTJstDvetCHZPgktXL7BpdOF1Fe_O7h-j98WE1fU4Xb0_z6WSRlhRUlxaZAikK0A4zg8sMBFUgBLfOZRYUL5R0Bc5cYQgBLTQxzGFDBFBwUkqgQzQ_esugt_mu9bVuD3nQPv8JQrvOddt5U9m8NzBlmJIKKHMy07I0xmnOpQXMBOldd0fXWve4b1zoWm1qH00-EUB4hoF8fxz9Q_VT2tqb0Fjn-_xP4f6ksLG66jYxVB-dD008Bb8Ap3F2iQ</recordid><startdate>20190531</startdate><enddate>20190531</enddate><creator>Cattaneo, Ruggero</creator><creator>Pietropaoli, Davide</creator><creator>Cooper, Barry C</creator><creator>Cappare, Dino</creator><creator>Ortu, Eleonora</creator><creator>Monaco, Annalisa</creator><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>DOA</scope></search><sort><creationdate>20190531</creationdate><title>A New Device Improves Signs and Symptoms of TMD</title><author>Cattaneo, Ruggero ; Pietropaoli, Davide ; Cooper, Barry C ; Cappare, Dino ; Ortu, Eleonora ; Monaco, Annalisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d319t-b89176b1af04c0d816391665eff8e195b97fb08fbc221a6a2c4f0c26131f77713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cattaneo, Ruggero</creatorcontrib><creatorcontrib>Pietropaoli, Davide</creatorcontrib><creatorcontrib>Cooper, Barry C</creatorcontrib><creatorcontrib>Cappare, Dino</creatorcontrib><creatorcontrib>Ortu, Eleonora</creatorcontrib><creatorcontrib>Monaco, Annalisa</creatorcontrib><collection>Directory of Open Access Journals</collection><jtitle>Pain research & management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cattaneo, Ruggero</au><au>Pietropaoli, Davide</au><au>Cooper, Barry C</au><au>Cappare, Dino</au><au>Ortu, Eleonora</au><au>Monaco, Annalisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A New Device Improves Signs and Symptoms of TMD</atitle><jtitle>Pain research & management</jtitle><date>2019-05-31</date><risdate>2019</risdate><volume>2019</volume><issn>1203-6765</issn><eissn>1918-1523</eissn><abstract>Background. Temporomandibular joint dysfunction (TMD) therapy remains an open challenge for modern dentistry. Herein, we propose a new neuromuscular lingual device able to reduce signs and symptoms of TMD in female patients with chronic orofacial pain. Methods. 50 females with myofascial TMD according to RDC/TMD were randomly assigned to study (n = 25) and control groups (n = 25). At T0, both groups received sEMG/KNG and pain evaluation by the VAS scale. The study group received the ELIBA device (lingual elevator by Balercia) constructed under ULF-TENS (ultra-low-frequency transcoutaneous electrical nervous stimulation). Subjects were instructed to use ELIBA at least for 16h/day. After 6 months (T1), both groups underwent to sEMG/KNG and VAS revaluation. Results. T1 study group compared to controls showed a significant reduction in total (p < 0.0001) and mean (p < 0.0001) sEMG values, as well as a significant increase in both maximum vertical mouth opening (p = 0.003) and maximum velocity in mouth opening (p = 0.003) and closing (p < 0.0001). Interestingly, a significant reduction in pain measured by VAS (p < 0.0001) was reported. Conclusions. After 6 months, the ELIBA device is able to significantly reduce TMD-associated myogenous pain and to promote the enhancement of sEMG/KNG values. Practical Implications. ELIBA can be considered as a new device, potentially useful for head-neck pain relief in patients suffering from chronic TMD. In addition, its use promotes a muscles relaxation inducing freeway space increase. This characteristic makes it particularly useful for rehabilitation of patients with not enough space for construction of conventional orthotics or neuromuscular bites.</abstract><pub>John Wiley & Sons, Inc</pub><doi>10.1155/2019/5646143</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1203-6765 |
ispartof | Pain research & management, 2019-05, Vol.2019 |
issn | 1203-6765 1918-1523 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_22149c4979134f78a7dccfa557e10462 |
source | ProQuest - Publicly Available Content Database; PubMed Central; Wiley-Blackwell Open Access Titles(OpenAccess) |
title | A New Device Improves Signs and Symptoms of TMD |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A30%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20New%20Device%20Improves%20Signs%20and%20Symptoms%20of%20TMD&rft.jtitle=Pain%20research%20&%20management&rft.au=Cattaneo,%20Ruggero&rft.date=2019-05-31&rft.volume=2019&rft.issn=1203-6765&rft.eissn=1918-1523&rft_id=info:doi/10.1155/2019/5646143&rft_dat=%3Cgale_doaj_%3EA612580121%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d319t-b89176b1af04c0d816391665eff8e195b97fb08fbc221a6a2c4f0c26131f77713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A612580121&rfr_iscdi=true |